Pediatrics

Researchers analyzed liveborn infant data from January 2020 to June 2024 to determine prevalence, cause, and treatment strategies for pain among preterm infants.

Researchers analyzed overall prescription stimulant dispensing trends among US children from 2017 to 2023.

Researchers analyzed the expansion of HPV vaccination for mid-adults defined as people 26 years or older with increased HPV risk.

PROMIS scores demonstrated the disparities between reported pain and mental health outcomes.

Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Cases of meningococcal disease currently exceed prepandemic levels.

The COVID-19 pandemic negatively impacted mental health in young people, and additional targeted mental health resources are needed.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Compounded with lifestyle interventions, researchers compared liraglutide with a placebo to measure its efficacy amongst children under 12 years old.

According to various research studies, these are the most commonly used interventions patients consider for treating and managing childhood obesity.

Current recommendations suggest women receive the RSV vaccine between 32 and 36 weeks' gestational age.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

The drug will be available in pharmacies during the second half of 2024.

Altuviiio was first granted approval by the FDA in February 2023.

Check out this list of resources to share with patients who are managing an allergy or asthma diagnosis.

Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.

A study from the Children’s Hospital of Philadelphia found that a positive PCR test was not associated with an increased risk of a new asthma diagnosis in patients ages 1 to 16.

Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.

Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.

Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).

As a result of an increase in adolescent inpatient visits with a sexually transmitted infection (STI) diagnosis in 2020, further work is needed to improve STI care, particularly for this demographic.

The FDA states the revision to the emergency use authorization (EUA) is the next phase in the transition from the use of EUA-labeled nirmatrelvir and ritonavir to the use of NDA-labeled nirmatrelvir and ritonavir.

Although the risk of respiratory distress among infants exposed to SARS-CoV-2 is high, the odds of developing the condition decreased by 67% among neonates born to vaccinated mothers.